We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App




New Urinary Antigen Immunodiagnostic Assay Enables High-Throughput Qualitative Detection of Legionnaires' Disease

By LabMedica International staff writers
Posted on 18 Jul 2023
Print article
Image: The new LIAISON Legionella Urinary Ag assay is performed on the LIAISON CLIA analyzers (Photo courtesy of DiaSorin)
Image: The new LIAISON Legionella Urinary Ag assay is performed on the LIAISON CLIA analyzers (Photo courtesy of DiaSorin)

Legionnaires' Disease (LD), a severe form of atypical Community Acquired Pneumonia (CAP), is primarily caused by the Legionella species in patients needing hospitalization. L. pneumophila sg 1 is responsible for 50 to 80% of LD cases globally. Sg 4 and 6, along with L. longbeachae, L. micdadei, and L. bozemanii, contribute to the majority of the remaining non-L.pneumophila sg 1 LD cases. If misdiagnosed or left untreated, LD can quickly deteriorate, leading to increased mortality rates. The death rate from LD can reach 40-80% in untreated immuno-compromised patients, but can be reduced to 5-30% with accurate identification and proper case management. Now, a new assay improves the diagnosis of atypical pneumonia by providing precise identification of the LD.

DiaSorin (Saluggia, Italy) has introduced the novel LIAISON Legionella Urinary Antigen Immunodiagnostic Assay, approved in all countries recognizing the CE Mark, as a tool for diagnosing LD. The assay, which is conducted on the LIAISON CLIA analyzers, offers a highly automated solution for microbiology laboratories. Using a simple test procedure, LD can be identified in a mere 35 minutes, enabling prompt and focused antimicrobial treatment. The LIAISON Legionella Urinary Ag assay, with its innovative "dual-antigen" design, can detect two Legionella's antigens (LPS and PAL), enhancing its sensitivity and specificity. This empowers healthcare practitioners to accurately identify antigens of Legionella pneumophila and Legionella longbeachae.

"The launch of this new assay confirms our ability to position DiaSorin as a specialty player, able to provide innovative solutions with a high medical value," said Chen Even, Chief Commercial Officer of DiaSorin. "We are confident that our new assay will strongly contribute in discriminating etiological factors in severe atypical pneumonia."

Related Links:
DiaSorin 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.